Status:

COMPLETED

Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting

Lead Sponsor:

McGill University

Collaborating Sponsors:

Diabetes Canada

Conditions:

Diabetes Mellitus, Type 1

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Closed-loop system systems that are shown to alleviate the burden of carbohydrate counting without degrading glucose control are still lacking. In this proposal, the investigators aim to develop a nov...

Detailed Description

Meal carbohydrate content is the main determinant of prandial insulin needs, and consequently, accurate carbohydrate counting is recommended for type 1 diabetes. Advances in glucose sensors have motiv...

Eligibility Criteria

Inclusion

  • Males and females ≥ 18 years of age.
  • Clinical diagnosis of type 1 diabetes for at least 12 months. The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.
  • Insulin pump therapy for at least 6 months.
  • HbA1c ≤ 12% in the last 6 months.

Exclusion

  • Current or ≤ 1 month use of other antihyperglycemic agents (SGLT2, GLP-1, Metformin, Acarbose, etc.…).
  • Severe hypoglycemic episode within one month of admission.
  • Severe diabetic ketoacidosis episode within one month of admission.
  • Pregnancy.
  • Known or suspected allergy to the study drugs.
  • Gastroparesis.
  • Use of prokinetic drugs that stimulate gastric emptying (domperidone, cisapride, metoclopramide).
  • Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator.
  • Recent (\< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
  • Current use of glucocorticoid medication.
  • Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.
  • Failure to comply with team's recommendations (e.g. not willing to eat meals/snacks, not willing to change pump parameters, etc.).

Key Trial Info

Start Date :

February 8 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 19 2020

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT03800875

Start Date

February 8 2019

End Date

September 19 2020

Last Update

June 8 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

McGill University Health Centre

Montreal, Quebec, Canada, H4A 3J1

Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting | DecenTrialz